Journal of Labelled Compounds and Radiopharmaceuticals · 2006 · 16 citations · 15 references
Natural SciencesChemistryMedicinal ChemistryOrganic ChemistryOrganometallic ChemistrySynthetic Medicinal ChemistryChemoenzymatic SynthesisSolid-phase SynthesisFluorine-18 ChemistryFluorine-18 LabelingFluorine-18 RadiopharmaceuticalsRadiochemical Purity AssessmentRadiochemical SynthesisReversed-phase Solid-phase Extraction
Abstract N ‐(3‐[ 18 F]fluoropropyl)‐2 β ‐carbomethoxy‐3 β ‐(4‐iodophenyl)nortropane ([ 18 F]FP‐ β ‐CIT) was synthesized in a two‐step reaction sequence. In the first reaction, 1‐bromo‐3‐(nitrobenzene‐4‐sulfonyloxy)‐propane was fluorinated with no‐carrier‐added fluorine‐18. The resulting product, 1‐bromo‐3‐[ 18 F]‐fluoropropane, was distilled into a cooled reaction vessel containing 2 β ‐carbomethoxy‐3 β ‐(4‐iodophenyl)‐nortropane, diisopropylethylamine and potassium iodide. After 30 min, the reaction mixture was subjected to a preparative HPLC purification. The product, [ 18 F]FP‐ β ‐CIT, was isolated from the HPLC eluent with solid‐phase extraction and formulated to yield an isotonic, pyrogen‐free and sterile solution of [ 18 F]FP‐ β ‐CIT. The overall decay‐corrected radiochemical yield was 25 ± 5%. Radiochemical purity was > 98% and the specific activity was 94 ± 50 GBq/µmol at the end of synthesis. Copyright © 2006 John Wiley & Sons, Ltd.
15
Dopamine transporter imaging with fluorine-18-FPCIT and PET.
Ken Kazumata, Vijay Dhawan, Thomas Chaly et al. · PubMed · 1998 · 157 citations
Medicine, Neuroscience, Pharmacology +15
Michael R. Kilbourn, John A. Katzenellenbogen, Michael J. Welch · The Journal of Organic Chemistry · 1987 · 114 citations
Thomas Chaly, Vijay Dhawan, Ken Kazumata et al. · Nuclear Medicine and Biology · 1996 · 86 citations · Full text